Ribociclib plus everolimus or temozolomide for certain brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age must fit the study plan: Part 1 requires under 21 years old; overall study screening is 12 months to 39 years old (on the main screening pathway).
- You must have a confirmed high-grade glioma (HGG) or DIPG, or a localized HGG with the specific H3G34 (R/V) mutation (for the DHG stratum).
- Your tumor must have the required genetic (“molecular”) changes on the study’s screening test, and you must not have confirmed RB1 loss in a specific way (called biallelic).
- You must have finished radiation (photon or proton) recently and be able to start treatment on time after the radiation ends (not too early and not too late).
- Blood counts, kidney, liver, heart tests, and breathing oxygen levels must meet study thresholds.
- You must be able to swallow study medicines by mouth (no NG/NJ/G tube) for the ribociclib + everolimus part, and your seizures (if you have them) must be controlled with certain allowed medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.